Atlas Venture
Edit

Atlas Venture

http://www.atlasventure.com
Last activity: 13.11.2024
Active
Invests in categories: BioTechDrugDevelopmentHealthTechPlatformMedtechProductTechnologyPublicResearch
Portfolio
73
Persons
9
Mentions
243
Employees: 11-50
Investment Stage: Seed; Series A; Series B

Portfolio 73

DateNameWebsiteTotal RaisedLocation
19.07.2024GRO Biosci...grobio.com$87.4MCanada, On...
26.10.2023Aiolos Bioaiolosbio.com$245MUnited Sta...
26.10.2023Triveni Bi...triveni.bio$207MUnited Sta...
15.06.2023AAVantgard...aavantgardebio.com-Italy, Lom...
18.12.2022Mariana On...marianaoncology.com$175MUnited Sta...
18.12.2022Viela Biohorizontherapeutics.com$23MUnited Sta...
16.10.2022Matchpoint...matchpointtx.com$100MUnited Sta...
03.10.2022Pheon Ther...pheontx.com$120MUnited Kin...
18.05.2022Remix Ther...remixtx.com$211MUnited Sta...
20.04.2022Sionna The...sionnatx.com$293MUnited Sta...
Show more

Persons 9

DateFirst NameLast NameTitleLinkedInLocation
-MichaelGladstonePartner-
-BruceBoothDPhil, Par...-
-JasonRhodesPartner-
-AlisonButtsReceptioni...linkedin.c...-
-PeterBarrettPhD, Partn...-
-AimeeRaleighPhD, Princ...linkedin.c...-
-Jean-Franç...FormelaMD, Partne...-
-JuliaPianMD, Associ...linkedin.c...-
-AndreaDiMellaVice Presi...linkedin.c...-

Mentions in press and media 243

DateTitleDescription
13.11.2024Trace Neuroscience: A New Dawn in Genomic Medicine for ALSIn the realm of biopharmaceuticals, a new player has emerged, armed with ambition and a hefty $101 million in Series A funding. Trace Neuroscience is on a mission to reshape the landscape of genomic medicine, particularly for those grapplin...
13.11.2024Trace Neuroscience: $101 Million (Series A) Raised To Expand Genomic Medicine PlatformTrace Neuroscience – a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases – announced its launch with a $101 million Series A funding led by Third Rock Ventures, with partic...
28.10.2024Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New FundingIn the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn...
25.10.2024Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell MedicinesBe Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo...
07.10.2024Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For ObesityKailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million...
04.10.2024Triveni Bio: $115 Million (Series B) Closed To Advance Novel Antibody Treatments For I&I DisordersTriveni Bio, a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B to support pipeline expansion. The funding round was led by Goldman Sachs Alternatives with significant participatio...
30.07.2024BioIVT Appoints Dr. Judith Dunn and Dr. Auro Nair to its Board of DirectorsWESTBURY, N.Y., July 30, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the appointment of Dr. Judith Dunn and Dr. Auro Nair to its Board of Dir...
29.07.2024Scorpion Therapeutics: A Bold Leap in Precision OncologyScorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ...
27.07.2024Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology PipelineScorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co...
25.07.2024GRO Biosciences Secures $60 Million to Revolutionize Gout Treatment** **** In the bustling world of biotechnology, innovation is the lifeblood. GRO Biosciences, or GRObio, has just taken a giant leap forward. The company recently announced the closing of an oversubscribed $60.3 million Series B financing round....
Show more

Reviews 0

Sign up to leave a review

Sign up Log In